Coya Therapeutics, Inc. Operating Expenses
Coya Therapeutics, Inc. (COYA) reported Operating Expenses of $7.29 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-11
- Coya Therapeutics, Inc. operating expenses for the quarter ending 2026-06-30 was $7.29M, a 10.83% increase year-over-year.
- Coya Therapeutics, Inc. operating expenses for the quarter ending 2026-03-31 was $7.89M, a 0.55% decline year-over-year.
- Coya Therapeutics, Inc. operating expenses for the quarter ending 2025-12-31 was $9.99M, a 144.74% increase year-over-year.
- Coya Therapeutics, Inc. operating expenses for the quarter ending 2025-09-30 was $6.00M, a 34.76% increase year-over-year.
- Coya Therapeutics, Inc. operating expenses for fiscal 2025 was $30.50M, a 46.61% increase from fiscal 2024.
- Coya Therapeutics, Inc. operating expenses for fiscal 2024 was $20.80M, a 49.61% increase from fiscal 2023.
- Coya Therapeutics, Inc. operating expenses for fiscal 2023 was $13.91M, a 41.72% increase from fiscal 2022.
- Coya Therapeutics, Inc. operating expenses for fiscal 2022 was $9.81M, a 101.46% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $7.29M 10-Q · filed 2026-08-11 | $15.18M 10-Q · filed 2026-08-11 | $25.17M derived: sum of 3 quarters · filed 2026-08-11 | $31.17M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $7.89M 10-Q · filed 2026-05-12 | $17.88M derived: sum of 2 quarters · filed 2026-05-12 | $23.88M derived: sum of 3 quarters · filed 2026-05-12 | $30.46M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $9.99M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $15.99M derived: sum of 2 quarters · filed 2026-03-16 | $22.57M derived: sum of 3 quarters · filed 2026-08-11 | $30.50M 10-K · filed 2026-03-16 |
| 2025-09-30 | $6.00M 10-Q · filed 2025-11-12 | $12.58M derived: sum of 2 quarters · filed 2026-08-11 | $20.51M 10-Q · filed 2025-11-12 | $24.59M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $6.58M 10-Q · filed 2026-08-11 | $14.51M 10-Q · filed 2026-08-11 | $18.60M derived: sum of 3 quarters · filed 2026-08-11 | $23.05M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $7.93M 10-Q · filed 2026-05-12 | $12.02M derived: sum of 2 quarters · filed 2026-05-12 | $16.47M derived: sum of 3 quarters · filed 2026-05-12 | $23.13M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $4.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $8.53M derived: sum of 2 quarters · filed 2026-03-16 | $15.19M derived: sum of 3 quarters · filed 2026-03-16 | $20.80M 10-K · filed 2026-03-16 |
| 2024-09-30 | $4.45M 10-Q · filed 2025-11-12 | $11.11M derived: sum of 2 quarters · filed 2025-11-12 | $16.72M 10-Q · filed 2025-11-12 | $20.91M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $6.66M 10-Q · filed 2025-08-12 | $12.27M 10-Q · filed 2025-08-12 | $16.46M derived: sum of 3 quarters · filed 2025-08-12 | $20.02M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $5.61M 10-Q · filed 2025-05-13 | $9.80M derived: sum of 2 quarters · filed 2025-05-13 | $13.36M derived: sum of 3 quarters · filed 2025-05-13 | $16.62M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $4.19M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $7.75M derived: sum of 2 quarters · filed 2025-03-18 | $11.01M derived: sum of 3 quarters · filed 2025-03-18 | $13.91M 10-K · filed 2025-03-18 |
| 2023-09-30 | $3.56M 10-Q · filed 2024-11-06 | $6.82M derived: sum of 2 quarters · filed 2024-11-06 | $9.72M 10-Q · filed 2024-11-06 | $11.72M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $3.25M 10-Q · filed 2024-08-12 | $6.15M 10-Q · filed 2024-08-12 | $8.16M derived: sum of 3 quarters · filed 2024-08-12 | $10.82M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $2.90M 10-Q · filed 2024-05-09 | $4.90M derived: sum of 2 quarters · filed 2024-05-09 | $7.57M derived: sum of 3 quarters · filed 2024-05-09 | $11.01M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $4.67M derived: sum of 2 quarters · filed 2024-03-19 | $8.11M derived: sum of 3 quarters · filed 2024-03-19 | $9.81M 10-K · filed 2024-03-19 |
| 2022-09-30 | $2.66M 10-Q · filed 2023-11-08 | $6.11M derived: sum of 2 quarters · filed 2023-11-08 | $7.81M 10-Q · filed 2023-11-08 | |
| 2022-06-30 | $3.45M 10-Q · filed 2023-08-08 | $5.15M 10-Q · filed 2023-08-08 | ||
| 2022-03-31 | $1.70M 10-Q · filed 2023-05-10 | |||
| 2021-12-31 | $4.87M 10-K · filed 2023-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |